High Tumour PD-L1 Is Associated With Poor Outcomes in EGFR-Mutant Lung Cancer Treated With First Generation EGFR TKIs

被引：0
|
作者：
Liu, J. [1 ]
Itchins, M. [2 ]
Nagrial, A. [3 ]
Cooper, W. [4 ]
De Silva, M. [2 ]
Barnet, M. [5 ]
Varikatt, W. [6 ]
Sivasubramaniam, V. [7 ]
Davis, A. [8 ]
Gill, A. [2 ]
Blinman, P. [9 ]
Lee, K. [9 ]
Hui, R. [1 ]
Gao, B. [1 ]
Pavlakis, N. [2 ]
Clarke, S. [10 ]
Lee, J. [8 ]
Boyer, M. [8 ]
Kao, S. [8 ]
机构：
[1] Crown Princess Mary Canc Ctr, Dept Med Oncol, Westmead, NSW, Australia
[2] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW, Australia
[3] Blacktown Hosp, Blacktown, NSW, Australia
[4] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Nsw Hlth Pathol, Nsw Pathol, Camperdown, NSW, Australia
[5] Kinghorn Canc Ctr, Med Oncol, Darlinghurst, NSW, Australia
[6] Westmead Hosp, Tissue Pathol & Diagnost Oncol, Inst Clin Pathol & Med Res, Westmead, NSW, Australia
[7] St Vincents Hosp, Sydpath, Darlinghurst, NSW, Australia
[8] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia
[9] Concord Repatriat Gen Hosp, Concord, ACT, Australia
[10] Univ Sydney, Sydney, NSW, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR; PD-L1; primary resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.08
引用
收藏
页码：S588 / S589
页数：2
相关论文
共 50 条
  • [1] PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
    Bai, Yuchen
    Chen, Xiaoxia
    Hou, Likun
    Qian, Jun
    Jiang, Tao
    Zhou, Caicun
    Ciebiada, Maciej
    CANCER BIOLOGY & MEDICINE, 2018, 15 (04) : 434 - +
  • [2] Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer
    Lei, Si-Yu
    Xu, Hai-Yan
    Li, Hong-Shuai
    Yang, Ya-Ning
    Xu, Fei
    Li, Jun-Ling
    Wang, Zhi-Jie
    Xing, Pu-Yuan
    Hao, Xue-Zhi
    Wang, Yan
    THORACIC CANCER, 2023, 14 (24) : 2327 - 2337
  • [3] PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma
    Isobe, Kazutoshi
    Kakimoto, Atsushi
    Mikami, Tetuo
    Kaburaki, Kyohei
    Kobayashi, Hiroshi
    Yoshizawa, Takahiro
    Nakano, Yuta
    Makino, Takashi
    Otsuka, Hajime
    Sano, Go
    Sugino, Keishi
    Sakamoto, Susumu
    Takai, Yujiro
    Tochigi, Naobumi
    Iyoda, Akira
    Homma, Sakae
    ONCOLOGY REPORTS, 2018, 40 (01) : 331 - 338
  • [4] Characterization of PD-L1 Expression and Its Predictive and Prognostic Significance in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs
    Jiang, T.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
  • [5] High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Chen, Kun-Chieh
    Ku, Wen-Hui
    Su, Kang-Yi
    Chen, Jeremy J. W.
    Chen, Huei-Wen
    Yu, Sung-Liang
    Yang, Tsung-Ying
    Chang, Gee-Chen
    LUNG CANCER, 2019, 127 : 37 - 43
  • [6] Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors
    Liu, Jia
    Itchins, Malinda
    Nagrial, Adnan
    Cooper, Wendy A.
    De Silva, Madhawa
    Barnet, Megan
    Varikatt, Winny
    Sivasubramaniam, Vanathi
    Davis, Alexander
    Gill, Anthony J.
    Blinman, Prunella
    Lee, Kenneth
    Hui, Rina
    Gao, Bo
    Pavlakis, Nick
    Clarke, Stephen
    Lee, Jenny
    Boyer, Michael
    Kao, Steven
    LUNG CANCER, 2021, 155 : 28 - 33
  • [7] Acquired ALK Rearrangement in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR TKIs
    Wang, Q.
    Chen, R.
    Kang, J.
    Chen, H.
    Wang, B.
    Wang, Z.
    Zhou, Q.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S569 - S570
  • [8] PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway
    Li, Na
    Zuo, Ran
    He, Yuchao
    Gong, Wenchen
    Wang, Yu
    Chen, Liwei
    Luo, Yi
    Zhang, Cuicui
    Liu, Zhiyong
    Chen, Peng
    Guo, Hua
    CELL DEATH & DISEASE, 2024, 15 (08):
  • [9] The role of PD-L1 in EGFR-mutant non-small cell lung cancer
    Gao, Wentao
    Wang, Lingling
    Zhao, Yanyan
    Zhu, Lucheng
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [10] Clinical Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs Followed by Subsequent Osimertinib
    Yao, Y.
    Cheng, J.
    Kang, J.
    Li, X.
    Chen, H.
    Zhou, Q.
    Xu, C.
    Zhang, X.
    Su, J.
    Yan, H.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S671 - S671
12345